Actively Recruiting
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Led by Indapta Therapeutics, INC. · Updated on 2025-06-03
128
Participants Needed
12
Research Sites
322 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
CONDITIONS
Official Title
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For multiple myeloma patients: Diagnosed with multiple myeloma requiring systemic therapy with relapsed or refractory disease after 3 or more prior treatments
- For non-Hodgkin's lymphoma patients: Relapsed or refractory disease after 2 or more lines of chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy longer than 12 weeks as assessed by the investigator
You will not qualify if you...
- History of significant cardiac disease or impaired heart function
- Infection with HIV, active hepatitis B, or hepatitis C
- Active COVID-19 infection
- Untreated central nervous system tumor, epidural tumor metastasis, or brain metastasis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Valkyrie Clinical Trials
Los Angeles, California, United States, 90670
Actively Recruiting
2
Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center
Lake Mary, Florida, United States, 32746
Withdrawn
3
Emory University Hospital
Atlanta, Georgia, United States, 30322
Actively Recruiting
4
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
5
NYP/Weill Cornell Medical Center
New York, New York, United States, 10065
Withdrawn
6
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States, 27157
Actively Recruiting
7
University Hospitals Cleveland
Cleveland, Ohio, United States, 44106
Actively Recruiting
8
Providence Cancer Institute Franz Clinic
Portland, Oregon, United States, 97213
Withdrawn
9
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Actively Recruiting
10
SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
11
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
12
NEXT Oncology Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
I
Indapta Therapeutics, Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here